Neurogene (NGNE) Competitors $20.05 +0.30 (+1.49%) Closing price 03:54 PM EasternExtended Trading$20.00 -0.05 (-0.25%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NGNE vs. WVE, VERV, PAHC, AKBA, COLL, NTLA, PHVS, CRMD, RCUS, and SYREShould you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include WAVE Life Sciences (WVE), Verve Therapeutics (VERV), Phibro Animal Health (PAHC), Akebia Therapeutics (AKBA), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), Pharvaris (PHVS), CorMedix (CRMD), Arcus Biosciences (RCUS), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry. Neurogene vs. Its Competitors WAVE Life Sciences Verve Therapeutics Phibro Animal Health Akebia Therapeutics Collegium Pharmaceutical Intellia Therapeutics Pharvaris CorMedix Arcus Biosciences Spyre Therapeutics WAVE Life Sciences (NASDAQ:WVE) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership. Do institutionals & insiders hold more shares of WVE or NGNE? 89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 29.1% of WAVE Life Sciences shares are held by insiders. Comparatively, 11.6% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer WVE or NGNE? In the previous week, Neurogene had 7 more articles in the media than WAVE Life Sciences. MarketBeat recorded 7 mentions for Neurogene and 0 mentions for WAVE Life Sciences. Neurogene's average media sentiment score of 0.15 beat WAVE Life Sciences' score of 0.00 indicating that Neurogene is being referred to more favorably in the news media. Company Overall Sentiment WAVE Life Sciences Neutral Neurogene Neutral Is WVE or NGNE more profitable? Neurogene's return on equity of -36.16% beat WAVE Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets WAVE Life SciencesN/A -86.49% -37.20% Neurogene N/A -36.16%-32.51% Do analysts recommend WVE or NGNE? WAVE Life Sciences presently has a consensus price target of $20.50, suggesting a potential upside of 194.12%. Neurogene has a consensus price target of $46.17, suggesting a potential upside of 130.32%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Neurogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score WAVE Life Sciences 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Neurogene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more volatility and risk, WVE or NGNE? WAVE Life Sciences has a beta of -1.01, indicating that its stock price is 201% less volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Which has higher valuation and earnings, WVE or NGNE? Neurogene has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWAVE Life Sciences$108.30M10.01-$97.01M-$0.84-8.30Neurogene$930K307.36-$75.14M-$4.35-4.61 SummaryNeurogene beats WAVE Life Sciences on 8 of the 15 factors compared between the two stocks. Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NGNE vs. The Competition Export to ExcelMetricNeurogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$285.84M$2.89B$5.49B$9.01BDividend YieldN/A2.64%5.39%4.09%P/E Ratio-4.6121.5627.4320.06Price / Sales307.36281.29398.25108.31Price / CashN/A41.4736.1356.90Price / Book0.967.518.085.67Net Income-$75.14M-$55.05M$3.16B$248.47M7 Day Performance20.97%3.16%2.12%2.90%1 Month Performance-2.50%5.92%4.43%5.75%1 Year Performance-44.29%5.82%35.62%21.36% Neurogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NGNENeurogene3.8165 of 5 stars$20.05+1.5%$46.17+130.3%-48.6%$285.84M$930K-4.6190News CoverageWVEWAVE Life Sciences4.1595 of 5 stars$6.96+5.9%$20.50+194.5%+29.3%$1.01B$108.30M-8.29240VERVVerve Therapeutics3.318 of 5 stars$11.11+0.5%$14.75+32.8%+124.2%$985.92M$32.33M-5.27110High Trading VolumePAHCPhibro Animal Health3.5731 of 5 stars$24.46+2.4%$20.80-15.0%+67.3%$967.94M$1.02B31.361,940AKBAAkebia Therapeutics4.3589 of 5 stars$3.64-1.1%$6.75+85.4%+278.1%$966.50M$160.18M-17.33430Positive NewsInsider TradeCOLLCollegium Pharmaceutical4.0327 of 5 stars$29.88+0.2%$43.75+46.4%-4.8%$958.49M$631.45M24.49210NTLAIntellia Therapeutics4.6488 of 5 stars$9.23+0.3%$34.95+278.7%-51.6%$952.96M$57.88M-1.76600PHVSPharvaris1.4724 of 5 stars$17.42-3.2%$36.20+107.8%+5.8%$940.70MN/A-5.7930Gap UpCRMDCorMedix2.4257 of 5 stars$16.56+21.7%$15.83-4.4%+181.3%$923.09M$43.47M75.2830Analyst ForecastAnalyst RevisionHigh Trading VolumeRCUSArcus Biosciences2.8801 of 5 stars$8.65+0.3%$24.13+179.1%-41.4%$912.73M$258M-2.06500SYRESpyre Therapeutics1.5793 of 5 stars$14.68-2.2%$53.40+263.8%-34.8%$904.74M$890K-3.8973 Related Companies and Tools Related Companies WVE Alternatives VERV Alternatives PAHC Alternatives AKBA Alternatives COLL Alternatives NTLA Alternatives PHVS Alternatives CRMD Alternatives RCUS Alternatives SYRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NGNE) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
